TREATMENT of lung tumorsLUNG cancer treatmentTHERAPEUTIC use of antineoplastic agentsLUNG cancerSURVIVALLUNG tumorsTUMOR classificationCOMBINED modality therapyFor stage III non-small cell lung cancer (NSCLC), approximately a third of patients survive up to 5 years, with decreasing 5-year survival rates ...
Treatment for patients with unresectable, stage III NSCLC whose disease has not progressed following concurrent platinum-based chemoradiation changed significantly with the FDA approval of durvalumab in February 2018. The approval was based on findings from the double-blind, placebo controlled, international...
which we took part in, with nivolumab, had early data presented that suggested an increase with pneumonitis; we wanted to give nivolumab in this instance but had to wait for the full cohort to be analyzed of course. At this point, from a radiation toxicity point of view, I have no major...
radical treatment? Stage 3A NSCLC – are we offering enough radical treatment?Stage 3A NSCLC – are we offering enough radical treatment?doi:10.1016/S0169-5002(18)30157-0J. PriceP. JainP. BeckettLung Cancer
Induction chemotherapy plus radiotherapy followed by surgery, evaluated in a number of phase II studies, is an effective treatment for patients with stage III A non-small cell lung cancer (NSCLC). The ongoing phase III National Cancer Institute Intergroup study is evaluating concurrent chemotherapy (...
Patients with unresectable, histologically confirmed, stage IIIA/B NSCLC who were at least 18 years of age, treatment naive, have an ECOG performance status of 0 or 1, and acceptable laboratory and pulmonary function were enrolled to the single-cohort, phase 2 trial. They were re...
the doctors discuss new 5-year data from the PACIFIC trial showing improvement in progression-free and overall survival among patients taking durvalumab consolidation therapy. They also explain the design of an ongoing clinical trial in which patients with stage III unresectable NSCLC will receive durva...
Treatment with nivolumab and chemotherapy in patients with stage IIIA/B non–small cell lung cancer yielded significantly improved survival and responses, according to data from the phase 2 NADIM II study.
Stage III ANSCLCInduction chemotherapy plus radiotherapy followed by surgery, evaluated in a number of phase II studies, is an effective treatment for patients with stage III A non-small cell lung cancer (NSCLC). The ongoing phase III National Cancer Institute Intergroup study is evaluating ...
Multiple clinical trials have revealed the benefit of immunotherapy (IO) for NSCLC, including unresectable stage III disease. Our aim was to investigate the impact of IO use on treatment and outcomes of potentially resectable stage IIIA NSCLC in a broader nationwide patient cohort. We queried the ...